( October 9, 2026, 23:45 GMT | Official Statement) -- MLex Summary: Corcept Therapeutics moved for summary judgment on Teva Pharmaceuticals’ antitrust claims. In its motion, Corcept argued that "[t]hrough several rounds of motion to dismiss briefing, Teva convinced the court that its claims — based primarily on Corcept’s contract with a single specialty pharmacy (first Optime, and later Curant) — were plausible enough to merit discovery." But now, following the conclusion of discovery, "the undisputed evidence demonstrates that Teva’s exclusive dealing theory fails as a matter of law," Corcept added. See attached document. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.